2024 Agenda Revealed: 2nd Next Generation Ophthalmic Drug Delivery Summit
With Novartis joining the suprachoroidal race with their novel injector and Genentech’s re-designed sustained release formulations showing promise for wet AMD, there has never been a better time to unite with fellow retinal delivery experts to discuss the ophthalmic innovations in preclinical and clinical R&D.
To aid this comes the return of the 2nd Next Generation Ophthalmic Drug Delivery Summit this January, uniting 90+ device engineers, biochemists, preclinical and clinical experts to discuss how they are optimizing longer-lasting and less invasive delivery devices to the back of the retina.
Here’s a snapshot of the 23+ industry expert speakers:
- Jie Shen, Senior Research Fellow,AbbVie
- Marshall Huston, Associate Director, Janssen
- Paulina Jakubiak, Senior Scientist, Biologics Development, Genentech
- Fabio Baschiera, Global Clinical Leader, Ophthalmology,Bayer
- Sammy Bell, Senior Director, External Alternative Drug Product Development,Boehringer Ingelheim
- Riad Sherif, Chief Executive Officer,Oculis
This year’s conference includes a brand-new tracked workshop day with AbbVie, Clearside Biomedical, Opus Genetics, and more, split into Molecule R&D and Device R&D to ensure all bases are covered when discussing ocular drug and delivery device development.
Vice President, Preclinical Development at Clearside Biomedical said last year’s conference was an “explosion of scientific ideas, discussions and networking opportunities with a great agenda.”
January’s conference is promising to be even better and will be the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic.
For more information on the program, tickets and more, visit ophthalmic-drug-delivery.com